Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May;96(19):e6836.
doi: 10.1097/MD.0000000000006836.

Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis

Hong-Lei Yin  1 , Shi-Qi Yin, Qing-Yan Lin, Ying Xu, Hong-Wei Xu, Tao Liu
Affiliations
Review

Prevalence of comorbidities in chronic obstructive pulmonary disease patients: A meta-analysis

Hong-Lei Yin et al. Medicine (Baltimore). 2017 May.

Abstract

Background: This study compares the prevalence rates of comorbidities between chronic obstructive pulmonary disease (COPD) and non-COPD control patients reported in literature.

Method: Literature was searched in several electronic databases. After the selection of studies by following précised eligibility criteria, meta-analyses of odds ratios (ORs) were carried out with subgroup and sensitivity analyses under random effects model.

Results: Eleven studies (47,695,183 COPD and 47,924,876 non-COPD control patients' data) were used for meta-analysis. Average age of COPD patients was 66.66 ± 8.72 years of whom 55.4 ± 11.9% were males. The prevalence of cardiovascular comorbidities [OR 1.90, 95% confidence interval (95% CI) 1.59-2.28; P < .00001], cerebrovascular comorbidities (OR 1.84, 95% CI 1.47-2.31; P < .00001), hypertension (OR 1.45, 95% CI 1.31-1.61; P < .00001), diabetes mellitus (OR 1.22, 95% CI 1.07-1.38; P = .003), neurological and psychiatric disorders (OR 1.78, 95% CI 1.48-2.14; P < .00001), gut and renal disorders (OR 1.96, 95% CI 1.43-2.68; P < .00001), musculoskeletal disorders (OR 1.51, 95% CI 1.27-1.78; P < .00001), non-COPD respiratory comorbidities (OR 2.81, 95% CI 2.52-3.14; P < .00001), and cancer (OR 1.67, 95% CI 1.25-2.23; P = .0005) were significantly higher in COPD patients than in non-COPD controls.

Conclusion: COPD is associated with significantly higher comorbidities than in other diseases that should be taken into consideration in COPD control strategies.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
A flowchart of the literature search, study screening, and selection process.
Figure 2
Figure 2
Forest plot showing the significantly higher prevalence of cardiovascular and cerebrovascular comorbidities in COPD patients in comparison with non-COPD patients. CAD = coronary artery disease, CHF = congestive heart failure, CVA = cerebrovascular accident, CVD = cardiovascular disease, HD = heart disease, IHD = ischemic heart disease.
Figure 3
Figure 3
Forest plot showing the significantly higher prevalence of hypertension and diabetes mellitus.
See this image and copyright information in PMC

References

    1. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741–50. - PubMed
    1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013;380:2095–128. - PMC - PubMed
    1. Mannino DM, Brown C, Giovino GA. Obstructive lung disease in the United States from 1979 to 1993: an analysis using multiple-cause mortality data. Am J Respir Crit Care Med 1997;156:814–8. - PubMed
    1. Petty TL. Definitions, causes, course, and prognosis of chronic obstructive pulmonary disease. Respir Care Clin N Am 1998;4:345–58. - PubMed
    1. Brown JP, Martinez CH. Chronic obstructive pulmonary disease comorbidities. Curr Opin Pulm Med 2016;22:113–8. - PubMed

MeSH terms